Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

Umberto Restelli,1,2 Giuliano Rizzardini,3,4 Andrea Antinori,5 Adriano Lazzarin,6 Marzia Bonfanti,1 Paolo Bonfanti,7 Davide Croce1,2 1Centre for Research on Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Varese, Italy; 2School of P...

Full description

Bibliographic Details
Main Authors: Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D
Format: Article
Language:English
Published: Dove Medical Press 2017-06-01
Series:Therapeutics and Clinical Risk Management
Subjects:
Cost-effectiveness analysis
Dolutegravir
HIV
Italy
Online Access:https://www.dovepress.com/cost-effectiveness-analysis-of-dolutegravir-plus-backbone-compared-wit-peer-reviewed-article-TCRM

Internet

https://www.dovepress.com/cost-effectiveness-analysis-of-dolutegravir-plus-backbone-compared-wit-peer-reviewed-article-TCRM

Similar Items